Artigo
A thermostable mRNA vaccine against COVID-19
Registro en:
ZHANG, N.-N. et al. A thermostable mRNA vaccine against COVID-19. Cell, [S.l.], 2020. No prelo.
Autor
Zhang, Na-Na
Li, Xiao-Feng
Deng, Yong-Qiang
Zhao, Hui
Huang, Yi-Jiao
Yang, Guan
Huang, Wei-Jin
Gao, Peng
Zhou, Chao
Zhang, Rong-Rong
Guo, Yan
Sun, Shi-Hui
Fan, Hang
Zu, Shu-Long
Chen, Qi
He, Qi
Cao, Tian-Shu
Huang, Xing-Yao
Qiu, Hong-Ying
Nie, Jian-Hui
Jiang, Yuhang
Yan, Hua-Yuan
Ye, Qing
Zhong, Xia
Xue, Xia-Lin
Zha, Zhen-Yu
Zhou, Dongsheng
Yang, Xiao
Wang, You-Chun
Ying, Bo
Qin, Cheng-Feng
Institución
Resumen
There has been an urgent need of vaccines against coronavirus disease 2019 (COVID-19) due to the ongoing SARS-CoV-2 pandemic. Among all approaches, messenger RNA (mRNA) -based vaccine has emerged as a rapid and versatile platform to quickly respond to such a challenge. Here, we developed a lipid-nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 as a vaccine candidate (termed ARCoV). Intramuscular immunization of ARCoV mRNA-LNPs elicited robust neutralizing antibodies against SARS-CoV-2 as well as Th1-biased cellular response in mice and non-human primates. Two doses of ARCoV immunization in mice conferred complete protection against the challenge of a SARS-CoV-2 mouse adapted strain. Additionally, ARCoV was manufactured in liquid formulation and can be stored at room temperature for at least one week. This novel COVID-19 mRNA vaccine, ARCoV, is currently being evaluated in phase 1 clinical trials.